Microbial and protozoal deoxyribonucleic acid (DNA)

Microbial and protozoal deoxyribonucleic acid (DNA) represents a vital pharmacological target for a broad spectrum of anti-infective agents. In anaerobic bacteria and certain protozoa, the low redox potential allows for the selective reduction of nitroimidazole drugs, such as metronidazole, into reactive intermediates that cause extensive DNA strand breakage (StatPearls, 2023). Other classes of drugs, including diamidines like pentamidine, interact with the DNA minor groove, particularly in AT-rich regions of kinetoplast DNA, thereby inhibiting replication and transcription (NCBI, 2024). This target is essential for the survival, reproduction, and protein synthesis of the pathogen. While effective, drugs targeting DNA must achieve selectivity to avoid genotoxic effects on host mammalian DNA. Therapeutic strategies often focus on the unique structural features of microbial genomes or the specific metabolic pathways required to activate DNA-damaging prodrugs. Consequently, microbial DNA remains a primary target in the treatment of infections ranging from bacterial vaginosis to systemic protozoal diseases like leishmaniasis and trypanosomiasis (Katzung, 2021).

Other names

Bacterial DNAProtozoan DNAParasitic DNAGenomic DNAKinetoplast DNA

Drugs targeting microbial or protozoal DNA typically act through direct physical interaction or chemical modification. Nitroimidazoles like metronidazole are reduced to reactive intermediates in anaerobic environments, which then cause oxidative damage and lethal strand breakage of the DNA helix (StatPearls, 2023). Other agents, such as the diamidine pentamidine, bind non-covalently to the minor groove of the DNA, particularly in AT-rich regions, interfering with essential replication and transcription processes (NCBI, 2024). Some agents may also act as intercalators or cause DNA cross-linking, effectively halting the pathogen's ability to maintain genomic integrity (Katzung, 2021).